- Report
- March 2025
- 94 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- November 2024
- 146 Pages
Global
From €2139EUR$2,250USD£1,797GBP
- Report
- March 2025
- 193 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- March 2025
- 387 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 413 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 136 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 136 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- October 2024
- 244 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- January 2025
- 182 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 160 Pages
Global
From €4724EUR$4,969USD£3,968GBP

The Antiplatelet Drugs market within the context of Cardiovascular Drugs is a rapidly growing sector of the pharmaceutical industry. Antiplatelet drugs are used to reduce the risk of heart attack and stroke by preventing the formation of blood clots. These drugs are used to treat a variety of cardiovascular conditions, including coronary artery disease, peripheral artery disease, and atrial fibrillation. Commonly prescribed antiplatelet drugs include aspirin, clopidogrel, ticagrelor, and prasugrel.
These drugs are typically taken orally, and are often prescribed in combination with other medications. In addition to reducing the risk of heart attack and stroke, antiplatelet drugs can also reduce the risk of other cardiovascular complications, such as deep vein thrombosis and pulmonary embolism.
Some of the major companies in the Antiplatelet Drugs market include Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Bristol-Myers Squibb. Show Less Read more